ZFP64 Promotes Gallbladder Cancer Progression Through Recruiting HDAC1 to Activate NOTCH1 Signaling Pathway
Overview
Authors
Affiliations
The lack of meaningful and effective early-stage markers remains the major challenge in the diagnosis of gallbladder cancer (GBC) and a huge barrier to timely treatment. Zinc finger protein 64 (ZFP64), a member of the zinc finger protein family, is considered to be a promising predictor in multiple tumors, but its potential effect in GBC still remains unclear. Here, we identified that ZFP64 was a vital regulatory protein in GBC. We found that ZFP64 expressed higher in GBC gallbladder carcinoma tissues than in normal tissues and was positively correlated with poor prognosis. Furthermore, ZFP64 was responsible for the migration, invasion, proliferation, anti-apoptosis, and epithelial mesenchymal transition (EMT) of GBC cells in vitro and in vivo. Mechanistically, through Co-IP assay, we confirmed that ZFP64 recruits HDAC1 localized to the promoter region of for deacetylation and therefore inhibits expression. The downregulation of NUMB enhanced the activation of the Notch1 signaling pathway, which is indispensable for the GBC-promotion effect of ZFP64 on GBC. In conclusion, ZFP64 regulated GBC progression and metastasis through upregulating the Notch1 signaling pathway, and thus ZFP64 is expected to become a new focus for a GBC prognostic marker and targeted therapy.
Zhang K, Guo L, Li X, Hu Y, Luo N J Transl Med. 2025; 23(1):247.
PMID: 40022222 PMC: 11871786. DOI: 10.1186/s12967-025-06246-3.
KDM1A-mediated ZFP64 demethylation activates CENPL to promote epithelial ovarian cancer progression.
Wang J, Fang X, Xing Y, Ding M, Zhu L, Wang M Cytotechnology. 2024; 77(1):10.
PMID: 39628712 PMC: 11609140. DOI: 10.1007/s10616-024-00671-w.
ZFP64 drives glycolysis-mediated stem cell-like properties and tumorigenesis in breast cancer.
Sun J, Liu J, Hou Y, Bao J, Wang T, Liu L Biol Direct. 2024; 19(1):83.
PMID: 39294751 PMC: 11409756. DOI: 10.1186/s13062-024-00533-7.
New trends in diagnosis and management of gallbladder carcinoma.
Pavlidis E, Galanis I, Pavlidis T World J Gastrointest Oncol. 2024; 16(1):13-29.
PMID: 38292841 PMC: 10824116. DOI: 10.4251/wjgo.v16.i1.13.